The estimated Net Worth of Health Quest Partners, L.P.... is at least $57.8 Million dollars as of 12 May 2020. Health P owns over 250,000 units of Castle Biosciences stock worth over $44,483,894 and over the last 5 years Health sold CSTL stock worth over $13,279,250.
Health has made over 7 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently Health sold 250,000 units of CSTL stock worth $8,625,000 on 12 May 2020.
The largest trade Health's ever made was selling 250,000 units of Castle Biosciences stock on 12 May 2020 worth over $8,625,000. On average, Health trades about 66,071 units every 41 days since 2019. As of 12 May 2020 Health still owns at least 1,433,577 units of Castle Biosciences stock.
You can see the complete history of Health P stock trades at the bottom of the page.
Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold und Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences executives and other stock owners filed with the SEC include: